Virksomhedsform
Anpartsselskab
Etableret
2001
Størrelse
Store
Ansatte
1.140
Omsætning
3.451 MDKK
Bruttofortj.
1.005 MDKK
Primært resultat (EBIT)
659 MDKK
Årets resultat
470 MDKK
Egenkapital
4.549 MDKK
annonce

Flere nøgletal og analyser?

Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!

Rang Årets resultat

Rang i branche
2/129
"Top 10%"
Rang i Danmark
343/342.443
"Top 10%"

Direktion top 3

Lars Petersen 2Direktør

Bestyrelse top 3

Toshihisa Iida 2Bestyrelsesformand
Lars Petersen 2Bestyrelsesmedlem
Yoshiki Kimura 2Bestyrelsesmedlem

Tegningsregler

Selskabet tegnes af et bestyrelsesmedlem alene. Bestyrelsen kan via fuldmagt bemyndige en person eller flere personer til at tegne på Selskabets vegne.

Stamoplysninger baseret på CVR

NavnFujifilm Diosynth Biotechnologies Denmark Aps
CVR26060702
AdresseBiotek Allé 1, 3400 Hillerød
BrancheFremstilling af farmaceutiske præparater [212000]
Etableret01-06-2001 (22 år)
Første regnskabsperiode01-06-2001 til 31-12-2001
VirksomhedsformAnpartsselskab
Antal ansatte1569 (årsværk:1547)
ReklamebeskyttelseNej
RevisorKpmg P/S siden 01-08-2019
Regnskabsperiode01-04 til 31-03
Selskabskapital390.000 DKK
385.000 DKK (10-04-2008 - 06-05-2008)
380.000 DKK (15-01-2008 - 09-04-2008)
375.000 DKK (01-10-2007 - 14-01-2008)
370.000 DKK (07-08-2007 - 30-09-2007)
365.000 DKK (20-04-2007 - 06-08-2007)
Vedtægter seneste27-10-2021

Medlem af brancherne

Formål

Selskabets formål er at drive produktions- og handelsvirksomhed og at besidde kapitalandele i andre virksomheder samt at drive anden virksomhed, der efter direktionens skøn er forbunden hermed.

Regnskab

 202320222021
Valuta/enhed000' DKK000' DKK000' DKK
Omsætning
3.450.897
+12%
3.068.983
+13%
2.727.431
-
Bruttofortjeneste
1.004.857
+72%
583.823
+18%
494.437
-
Årets resultat
470.320
+120%
213.460
+106%
103.550
-
Egenkapital
4.549.198
+12%
4.078.878
+6%
3.865.418
-
Balance
13.683.660
+62%
8.455.622
+45%
5.848.427
-

Ledelsesberetning

An improvement in the activities in the business areas resulting in a higher than expected revenue and much higher profit.
Revenue and Profit
The company delivered a total revenue of DKK 3,450.9 million in financial year 2022/23 compared to DKK 3,069.0 million in financial year 2021/22.

The growth in revenue was 12.4% compared to the financial year 2021/22 and exceeded the expectations of a revenue at the same level as financial year 2021/22.

Profit before tax was DKK 601.6 million compared to DKK 271.9 million in financial year 2021/22. Net profit was DKK 470.3 million in 2022/23 compared to DKK 213.5 million in 2021/22 while the expected profit before tax for financial year 2022/23 was between DKK 275-350 million. The improvement can be attributed to the increased manufacturing activities in the drug substance manufacturing area.
Investments
FDBD invested a total of DKK 4,303.3 million in tangible fixed assets in 2022/23. This is a significant increase compared to 2021/22 where the investments equalled DKK 2,617.9 million. The investments are covering the expansion of the facility in building for the future project as well as the operational capital investment to support the continuous manufacturing. The investments are funded through cash flow from operations and loan arrangements with FUJIFILM Corporation Europe.
Total assets increased in 2022/23. At year-end the total assets were DKK 13,683.7 million compared to the DKK 8,455.6 million in the financial year 2021/22.
Equity
At the end of the financial year the equity shows DKK 4,549.2 million. The equity ratio decreased from 48.2% in 2021/22 to 33.2% in 2022/23. The decrease in the equity ratio is mainly due to the significant increase in the internal loans to support the current expansion projects.

Transfer Pricing Audit income year 2020
The Danish Tax Authorities (DTA) has reviewed FDBDs Transfer Pricing documentation for the income year 2020. DTA has challenged FDBD payment of Royalty to Fujifilm Corporate in income year 2020.

Consequently, the Danish Tax Authorities have suggested to increase the taxable income of FDBD for income year 2020, by DKK 46.0 million, with a tax value of DKK 10.1 million by only allowing royalty payments on “new customers”. FDBD does not agree with the suggested increase of taxable income, so the review is currently ongoing with DTA, FDBD and Fujifi lm Corporate. As a result of FDBD’s assessments and evaluation of DTA’s suggestion, FDBD has not recorded any provisions related to this transfer pricing audit in these financial statements.
Uncertainties as to recognition or measurement
The assessment of uncertain tax positions is based on determine whether it is probable that a liability may be recognized and measure the amount of the liability based on the probability of different outcomes.
28-09-2023

Kort